C3 and Hepatic fibrosis: Markers might be used alone to monitor early-stage patients or in combination with already established biomarkers in the field, such as PRO-C3 a marker of active fibrogenesis, or the two composite scores “A PRO-C3-based fibrosis algorithm that included age, presence of diabetes, PRO-C3, and platelet count” (ADAPT) or the “Enhanced Liver Fibrosis score” (ELF), developed for the detection of advanced liver fibrosis in patients with liver disease, that are best suited for the identification and monitoring of late-stage liver fibrosis, F3-F4 [2,3].